CN102335392B - Rhizoma smilacis chinensis dispersion tablet and preparing process thereof - Google Patents
Rhizoma smilacis chinensis dispersion tablet and preparing process thereof Download PDFInfo
- Publication number
- CN102335392B CN102335392B CN 201110299723 CN201110299723A CN102335392B CN 102335392 B CN102335392 B CN 102335392B CN 201110299723 CN201110299723 CN 201110299723 CN 201110299723 A CN201110299723 A CN 201110299723A CN 102335392 B CN102335392 B CN 102335392B
- Authority
- CN
- China
- Prior art keywords
- parts
- filtrate
- rhizoma
- add
- rhizoma smilacis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title abstract description 9
- 230000008569 process Effects 0.000 title abstract description 7
- 239000006185 dispersion Substances 0.000 title abstract description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 14
- 206010061218 Inflammation Diseases 0.000 claims abstract description 13
- 230000004054 inflammatory process Effects 0.000 claims abstract description 13
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims abstract description 8
- 108010011485 Aspartame Proteins 0.000 claims abstract description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 7
- 229930195725 Mannitol Natural products 0.000 claims abstract description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000605 aspartame Substances 0.000 claims abstract description 7
- 235000010357 aspartame Nutrition 0.000 claims abstract description 7
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 7
- 229960003438 aspartame Drugs 0.000 claims abstract description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 7
- 239000000594 mannitol Substances 0.000 claims abstract description 7
- 235000010355 mannitol Nutrition 0.000 claims abstract description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 7
- 239000000741 silica gel Substances 0.000 claims abstract description 7
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 7
- 208000006374 Uterine Cervicitis Diseases 0.000 claims abstract description 5
- 206010008323 cervicitis Diseases 0.000 claims abstract description 5
- 239000000706 filtrate Substances 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 244000261559 Smilax china Species 0.000 claims description 9
- 235000000485 Smilax china Nutrition 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000007919 dispersible tablet Substances 0.000 claims description 9
- 240000009022 Smilax rotundifolia Species 0.000 claims description 8
- 235000003205 Smilax rotundifolia Nutrition 0.000 claims description 8
- 241000628997 Flos Species 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 230000001684 chronic effect Effects 0.000 abstract description 4
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 235000003392 Curcuma domestica Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 229940079832 sodium starch glycolate Drugs 0.000 abstract 1
- 229920003109 sodium starch glycolate Polymers 0.000 abstract 1
- 239000008109 sodium starch glycolate Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 23
- 229940079593 drug Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- KRKRAOXTGDJWNI-UHFFFAOYSA-N 4-Methylglutamic acid Chemical compound OC(=O)C(C)CC(N)C(O)=O KRKRAOXTGDJWNI-UHFFFAOYSA-N 0.000 description 2
- RCCMXKJGURLWPB-UHFFFAOYSA-N 4-methyleneglutamic acid Chemical compound OC(=O)C(N)CC(=C)C(O)=O RCCMXKJGURLWPB-UHFFFAOYSA-N 0.000 description 2
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- DLUTTXMPJCVUFR-HJCIYZGTSA-N Parillin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@@H]1C[C@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@@H](C)CC1)O5)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DLUTTXMPJCVUFR-HJCIYZGTSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000008777 kaempferol Nutrition 0.000 description 2
- -1 kaempferol glucoside Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- PADQINQHPQKXNL-LSDHHAIUSA-N (+)-dihydrokaempferol Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C=C1 PADQINQHPQKXNL-LSDHHAIUSA-N 0.000 description 1
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- YQEMAEKYNNOCBY-IEMDQPGHSA-N Gracillin Chemical group O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YQEMAEKYNNOCBY-IEMDQPGHSA-N 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- RAYJUFCFJUVJBB-UHFFFAOYSA-N dihydrokaempferol Natural products OC1Oc2c(O)cc(O)cc2C(=O)C1c3ccc(O)cc3 RAYJUFCFJUVJBB-UHFFFAOYSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 description 1
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 description 1
- CASUWPDYGGAUQV-UHFFFAOYSA-M potassium;methanol;hydroxide Chemical compound [OH-].[K+].OC CASUWPDYGGAUQV-UHFFFAOYSA-M 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a rhizoma smilacis chinensis dispersion tablet and a preparing process thereof. The rhizoma smilacis chinensis dispersion tablet is prepared from the following components in parts by weight: 600 parts of rhizoma smilacis chinensis, 2000 parts of rhizoma cyperi, 1000 parts of herba leonuri, 1000 parts of caulis mahoniae, 800 parts of caulis spatholobi, 800 parts of ligusticum wallichii, 600 parts of common turmeric, 300 parts of safflower, 300 parts of red dates, 1000 parts of angelica, 50 parts of microcrystalline cellulose, 125 parts of mannitol, 12.5 parts of aspartame, 20 parts of micronization silica gel, 67.5 parts of sodium starch glycolate and 5 parts of magnesium stearate. The dispersion tablet is convenient to use and has low cost, high bioavailability and a good curative effect for treating gynecological inflammation such as cervicitis, chronic pelvic inflammatory disease and the like. The invention also provides a simple and feasible preparing process.
Description
Technical field
The present invention relates to a kind of China root greenbrier dispersible tablet and preparation technology thereof of the preparation take Rhizoma Smilacis Bockii extract as primary raw material; Belong to field of medicaments.
Background technology
Rhizoma Smilacis Bockii medicine name Rhizoma Smilacis Chinensis has another name called Rhizoma Smilacis Scobinicaulis, belongs to liliaceous plant, and property is sweet, warm, and is nontoxic, can wind-damp dispelling, diuresis, detumescence poison, clinically can be used for treating surgery actute infection, rheumatic arthritis, cancerous protuberance etc.Rhizoma Smilacis Bockii is the dry rhizome of liliaceous plant Rhizoma Smilacis Chinensis (Smilax china L); Begin to be stated from " Mingyi Bielu ", have another name called Rhizoma Smilacis Chinensis, Rhizoma Smilacis Bockii, horse Galle, muscles and bones pillar, red light fruit in the Compendium of Material Medica.The property sweet, sour, flat, the merit of tool expelling wind and removing dampness, removing toxic substances and promoting subsidence of swelling.Can be used for wind-damp dispelling, diuresis, detumescence poison, control arthralgia, edema, furuncle.'Jingangteng ' is used for the treatment of gynecological inflammation such as adnexitis, chronic pelvic inflammatory disease determined curative effect, and toxic and side effects is few.Rhizoma Smilacis Bockii mainly contains kaempferol, kaempferol glucoside, dihydrokaempferol, Quercetin, isorhamnetin, smilacin A, B, C, diosgenin A, dioscin, Gracillin unit, methyl diosgenin, the former Rhizoma Dioscoreae soap of 2-Alpha-hydroxy-methyl time aglycon, 4-methylene-glutamic acid, 4-methyl-glutamic acid, smilacin etc.; In known plant chemical ingredient, flavonoid and steroid saponin are the main effective ingredient of Rhizoma Smilacis Bockii.
Gynecological inflammation mainly refers to women genitals's inflammation.Comprise the female vulva inflammation that a variety of causes causes, vaginitis, cervicitis, the diseases such as pelvic inflammatory disease, the caused misery of gynecological inflammation has middle hypogastralgia, lumbago, menoxenia, Pruritus, dysmenorrhea, leucorrhea is many, the symptoms such as sexual anhedonia, gynecological inflammation is women's commonly encountered diseases, easily send out disease, gynecological inflammation not only can be given a birth because of the woman, artificial abortion, medicine stream and menstrual period, tired, endogenous courses of infection in the situation that the body constitution such as operation reduce and getting, also can be unclean because of female article, menstrual period are unhygienic, sterilization does not sternly suffer exogenous courses of infection and suffers from unclean sexual life and the operation process, having a strong impact on for a long time women's physical and mental health, many patients are ashamed of seeking medical advice or not free hospital treatment, affect again and again the state of an illness adversely, so that caused serious consequence. and the treatment of all kinds of gynecological checking be unable to do without medicine for many years always, the application physiotherapy that has in chronic phase, but how unsatisfactory on the curative effect, and relapse rate is quite high.
At present, the clinical treatment gynecological inflammation mainly contains two aspect means, a kind of is that the Western medicine antibiotic is treated, although the method can be alleviated some clinical symptoms, ties up heavily fortified point because some reasons such as the easy recurrent of gynecological inflammation and Antibiotic resistance cause antibiotic treatment to be taken a step; Another kind is to use Chinese medicine lotion, and the method patient's medication in therapeutic process is very difficult, and because most Chinese medicine lotions have very heavy flavour of a drug, brings huge negative effect to the patient, thereby cause the compliance of patient's medication poor.
Summary of the invention
The object of the present invention is to provide a kind of taking convenience, be beneficial to storage, bioavailability is high, to treatment gynecological inflammation such as the curative effect of disease such as cervicitis, chronic pelvic inflammatory disease are definite, toxic and side effects is few China root greenbrier dispersible tablet and preparation technology thereof.
Technical scheme provided by the invention is: a kind of China root greenbrier dispersible tablet is comprised of the one-tenth branch of following weight proportioning: Rhizoma Smilacis Bockii 6000, Rhizoma Cyperi 2000, Herba Leonuri 1000, Caulis Mahoniae 1000, Caulis Spatholobi 800, Rhizoma Chuanxiong 800, Radix Curcumae 600, Flos Carthami 300, Fructus Jujubae 300, Radix Angelicae Sinensis 100, microcrystalline Cellulose 50, mannitol 125, aspartame 12.5, micropowder silica gel 20, carboxymethylstach sodium 67.5, magnesium stearate 5.
Its preparation technology's flow process is:
A) extract: get Rhizoma Smilacis Bockii, decoct with water secondary, each 3 hours, add the water of 8 times of weight the first time, filter and collect filtrate, then add for the second time the water of 4 times of weight, filter collection filtrate, merge the filtrate of twice collection.
B) get Rhizoma Cyperi, Herba Leonuri, Caulis Mahoniae, Caulis Spatholobi, Rhizoma Chuanxiong, Radix Curcumae, the decocting that Flos Carthami, Fructus Jujubae, Radix Angelicae Sinensis add 5 times of weight boiled 3 hours, filtered, and collected filtrate.
C) concentrated: with step a) and step b) filtrate merge, in 60 ℃ filtrate is concentrated into the clear paste that relative density is 1.06～1.09g/ml.
D) precipitate with ethanol: add ethanol, make to contain the alcohol amount and reach 50% (volume ratio), and to regulate pH with the NaOH of 1M be 7.5, left standstill 24 hours, filtration in filtrate behind the Recycled ethanol, and is concentrated into the thick paste shape with filtrate, and 70 ℃ of vacuum dryings become dry extract.
E) granulate: get above-mentioned dry extract, pulverize, cross 100 mesh sieves, add microcrystalline Cellulose, mannitol, aspartame, micropowder silica gel, mixing, granulation, drying.
F) add carboxymethylstach sodium, magnesium stearate, mixing, tabletting, and get final product.
This product is that taupe is to tan tablet; Sweet, little hardship of distinguishing the flavor of.
Usage and consumption: swallow or add aqueous dispersion after take.One time 5,3 times on the one.
The specific embodiment
Embodiment 1
A kind of China root greenbrier dispersible tablet is comprised of following compositions: Rhizoma Smilacis Bockii 6000g, Rhizoma Cyperi 2000g, Herba Leonuri 1000g, Caulis Mahoniae 1000g, Caulis Spatholobi 800g, Rhizoma Chuanxiong 800g, Radix Curcumae 600g, Flos Carthami 300g, Fructus Jujubae 300, Radix Angelicae Sinensis 100g, microcrystalline Cellulose 50g, mannitol 125g, aspartame 12.5g, micropowder silica gel 20g, carboxymethylstach sodium 67.5g, magnesium stearate 5g.
Its preparation technology's flow process is:
A) extract: get Rhizoma Smilacis Bockii 6000g, decoct with water secondary, each 3 hours, add the water of 8 times of weight the first time, filter and collect filtrate, then add for the second time the water of 4 times of weight, filter collection filtrate, merge the filtrate of twice collection.
B) get Rhizoma Cyperi 2000g, Herba Leonuri 1000g, Caulis Mahoniae 1000g, Caulis Spatholobi 800g, Rhizoma Chuanxiong 800g, Radix Curcumae 600g, Flos Carthami 300g, Fructus Jujubae 300g, Radix Angelicae Sinensis 100g, the decocting that adds 5 times of weight boiled 3 hours, filtered, and collected filtrate.
C) concentrated: with step a) and step b) filtrate merge, in 60 ℃ filtrate is concentrated into the clear paste that relative density is 1.06～1.09g/ml.
D) precipitate with ethanol: add ethanol, make to contain the alcohol amount and reach 50% (volume ratio), and to regulate pH with the NaOH of 1M be 7.5, left standstill 24 hours, filtration in filtrate behind the Recycled ethanol, and is concentrated into the thick paste shape with filtrate, and 70 ℃ of vacuum dryings become dry extract.
E) granulate: get above-mentioned dry extract, pulverize, cross 100 mesh sieves, add an amount of microcrystalline Cellulose, mannitol, aspartame, micropowder silica gel, mixing, granulation, drying.
F) add an amount of carboxymethylstach sodium, magnesium stearate, mixing is pressed into 1000, and get final product.
The product quality parameters of utilizing preparation technology of the present invention to obtain is as follows: table 1
Embodiment 2: the therapeutic effect experiment:
One, animal experiment:
1, trial drug: 1, medicine of the present invention (0.5g/ sheet), control drug: FUKE QIANJIN PIAN, 0.32g/ sheet (production of a thousand pieces of gold pharmaceutcal corporation, Ltd).
2, experiment process: said medicine is soaked in an amount of meat soup, and fully vibration makes its dissolving.Remove by filter insoluble medicinal residues, with aperture 0.22 μ m ultra micro filter filtration sterilization, it is for subsequent use that sterile liquid medicine is put 4 ℃ of Refrigerator stores.The experimental bacteria of cultivation in 37 ℃, 24 hours is inoculated in meat soup, puts 37 ℃ of common incubators, cultivated in 24 hours, turbidimetry is carried out count of bacteria, is deployed into 10 with meat soup
6CFU/ml bacterium liquid is for subsequent use.Use meat soup by 10% (250mg medicine/ml medicinal liquid, take the result of pharmacology preliminary experiment as basis, and with reference to the definite maximum safe and effective concentration of clinical common dose) carry out continuous two times of gradient dilutions for starting point, be added to successively on the 96 porocyte culture plates 0.2ml/ hole.Adding concentration is 10 again
6The experimental bacteria liquid 0.01ml/ hole of CFU/ml.Set up simultaneously the contrast of antibacterial and culture medium.Put 4 ℃ of effects 12 hours, in 37 ℃ of common incubators, cultivation in 48 hours, observed result.Be minimal inhibitory concentration (MIC) without the little drug level of bacterial growth Kongzui.Successively each culture without the bacterial growth hole is diluted 10 times with sterile distilled water again, draw the 0.01ml dibbling dull and stereotyped in plain agar, putting 37 ℃ of common incubators, cultivated in 48 hours, is minimal bactericidal concentration (MBC) without the corresponding medicine Cmin in bacterial growth dibbling zone.
3, result of the test:. the medicine group sees Table 2 to the antibacterial experiment result of 3 kinds of common reference cultures of gynecological.
Compare with the drugs compared group, there is significant difference P＜0.05.
Two, toxicity test:
Wistar Oral Administration in Rats administration said preparation 1.0g/kg is adopted in this experiment, successive administration 90 days, 2 weeks of Reversible observe, growth of animal state, movable diet, hematology, blood biochemical, organs and tissues structure all have no significant effect during observing the rat administration and after the drug withdrawal, wherein the said preparation consumption is 1.0g/kg, quite 20 times of quantity, show that clinical drug safety is reliable.
Three, analgesic experiment:
Mice acetic acid is caused the effect of writhing response: 30 of mices, be divided at random 3 groups, be administered once every day, gastric infusion is 5 days continuously, and behind last gastric infusion 1h, lumbar injection 0.6% glacial acetic acid 0.2ml/ only, observe mouse writhing number of times in the 20min, the results are shown in Table 3.
| Group | Mice number (only) | Writhing number of times (30min) |
| The normal saline group | 10 | 39.19 |
| Matched group | 10 | 10.78 |
| The present invention | 10 | 9.08 |
Four, antiinflammatory action:
Get 30 of rats, be divided at random 3 groups, be administered once every day, gavage medicine 7d, behind last administration 1h, in left sufficient plantar aponeurosis hemostasis 1% carrageenin 0.1ml/ only, behind the 3h, cut swollen foot from Mus left hind joint, weigh, peeling shreds, and steeps 40min in the 5ml normal saline, get supernatant 0.5ml, add 2ml 10.5N KOH methanol solution, isomerization 20min in 50 ℃ of water-baths adds methanol again and is diluted to 20ml, survey its optical density with 751 type spectrophotometer wavelength 278nm, try to achieve the PGE total content.The results are shown in Table 4.
| Group | Mice number (only) | PEG content (ug/g) |
| The normal saline group | 10 | 54.45 |
| Matched group | 10 | 23.18 |
| The present invention | 10 | 19.65 |
Clinical therapeutic efficacy:
Clinically use through 120 routine Patients with Pelvic Inflammatory Diseases, obtained good curative effect, statistical result is as follows: always cure 109 examples, invalid 11 examples, total effective rate 91%; Clinically use through 90 routine virus in patients with cervicitis, also obtained good curative effect, statistical result is as follows: always cure 72 examples, invalid 18 examples, total effective rate 80%.
Model case:
Case 1: Lee, woman, 45 years old.Patient's disease: lower abdomen has pain, and menstruation is unpunctual, and leucorrhea is many, and doing gynecologial examination to the People's Hospital, Lingbao City is serious symptom cervical erosion, and cervix uteri three degree are rotten to the corn.
Treatment: take the medicine of the present invention's preparation, one day three times, each 5, take continuously three courses for the treatment of, each one week of the course for the treatment of.Lower abdomen is not painful, and leucorrhea is normal, and cervix uteri is soft ruddy, and is smooth, and all are normal.
Case 2: chapter, woman, 33 years old.Patient's disease: recently menstruation is inaccurate, and leucorrhea is many, and pudendum is very itched, and lower abdomen has painful sense, pelvic inflammatory disease.Treatment: take the medicine of the present invention's preparation, one day three times, each 5, take continuously three courses for the treatment of, each one week of the course for the treatment of.Lower abdomen has slight painful sense, and itching of vagina disappears, and leucorrhea reduces, and inflammation disappears.
Although, above with general explanation and the specific embodiment detailed explanation having been done in this case, on basis of the present invention, can make some modifications or improvements it, this will be apparent to those skilled in the art.Therefore, the modification of doing without departing from theon the basis of the spirit of the present invention or improvement all belong to the scope of protection of present invention.
Claims (3)
1. a China root greenbrier dispersible tablet for the treatment of gynecological inflammation is characterized in that, is comprised of the one-tenth branch of following weight proportioning: Rhizoma Smilacis Bockii 6000, Rhizoma Cyperi 2000, Herba Leonuri 1000, Caulis Mahoniae 1000, Caulis Spatholobi 800, Rhizoma Chuanxiong 800, Radix Curcumae 600, Flos Carthami 300, Fructus Jujubae 300, Radix Angelicae Sinensis 100, microcrystalline Cellulose 50, mannitol 125, aspartame 12.5, micropowder silica gel 20, carboxymethylstach sodium 67.5, magnesium stearate 5.
2. the preparation method of China root greenbrier dispersible tablet as claimed in claim 1 is characterized in that:
A) extract: get Rhizoma Smilacis Bockii, decoct with water secondary, each 3 hours, add the water of 8 times of weight the first time, filter and collect filtrate, then add for the second time the water of 4 times of weight, filter collection filtrate, merge the filtrate of twice collection;
B) get Rhizoma Cyperi, Herba Leonuri, Caulis Mahoniae, Caulis Spatholobi, Rhizoma Chuanxiong, Radix Curcumae, Flos Carthami, Fructus Jujubae, Radix Angelicae Sinensis, the decocting that adds 5 times of weight boiled 3 hours, filtered, and collected filtrate;
C) concentrated: with step a) and step b) filtrate merge, in 60 ℃ filtrate is concentrated into the clear paste that relative density is 1.06～1.09g/ml;
D) precipitate with ethanol: add ethanol, make to contain the alcohol amount and reach 50%, and to regulate pH with the NaOH of 1M be 7.5, left standstill 24 hours, filtration, filtrate recycling ethanol, and be concentrated into the thick paste shape, 70 ℃ of vacuum dryings become dry extract;
E) granulate: get above-mentioned dry extract, pulverize, cross 100 mesh sieves, add microcrystalline Cellulose, mannitol, aspartame, micropowder silica gel, mixing, granulation, drying;
F) add carboxymethylstach sodium, magnesium stearate, mixing, tabletting, and get final product.
3. China root greenbrier dispersible tablet as claimed in claim 1 is characterized in that, described dispersible tablet is used for the treatment of pelvic inflammatory disease or cervicitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110299723 CN102335392B (en) | 2011-09-28 | 2011-09-28 | Rhizoma smilacis chinensis dispersion tablet and preparing process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110299723 CN102335392B (en) | 2011-09-28 | 2011-09-28 | Rhizoma smilacis chinensis dispersion tablet and preparing process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102335392A CN102335392A (en) | 2012-02-01 |
| CN102335392B true CN102335392B (en) | 2013-02-13 |
Family
ID=45511492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110299723 Expired - Fee Related CN102335392B (en) | 2011-09-28 | 2011-09-28 | Rhizoma smilacis chinensis dispersion tablet and preparing process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102335392B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104825724A (en) * | 2015-05-28 | 2015-08-12 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine preparation for chronic cervicitis postoperative rehabilitation |
-
2011
- 2011-09-28 CN CN 201110299723 patent/CN102335392B/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 复方氨酚葡锌分散片处方及其制备工艺研究;李萌 等;《中国现代应用药学》;20100331;第27卷(第3期);235-239 * |
| 李萌 等.复方氨酚葡锌分散片处方及其制备工艺研究.《中国现代应用药学》.2010,第27卷(第3期),235-239. |
| 治疗慢性盆腔炎中药的研究进展;王敏杰 等;《药物评价研究》;20101231;第33卷(第6期);461-466 * |
| 王敏杰 等.治疗慢性盆腔炎中药的研究进展.《药物评价研究》.2010,第33卷(第6期),461-466. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102335392A (en) | 2012-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102145111B (en) | Traditional Chinese medicine composition for treating colpitis mycotica and preparation method thereof | |
| CN108853404A (en) | A kind of compound Chinese medicinal preparation and preparation method thereof for treating skin and mucous membrane disease | |
| CN103800772A (en) | Gynecological external lotion for preventing and treating vagina inflammatory diseases and preparation method thereof | |
| CN101314004B (en) | Medicament for treating gynaecologic urinary system infection contamination and preparation method thereof | |
| CN101732668B (en) | Preparation method of traditional Chinese medicine composition for treating urinary system infection | |
| CN104721418B (en) | It is a kind of to be used to treat pharmaceutical composition of gynaecological imflammation and preparation method thereof and purposes | |
| CN101288754B (en) | Huyuebao preparation | |
| CN102949662B (en) | External traditional Chinese medicine preparation for treating female reproductive system inflammation and preparation method thereof | |
| CN102335392B (en) | Rhizoma smilacis chinensis dispersion tablet and preparing process thereof | |
| CN103041247A (en) | Traditional Chinese medicine suppository for curing colpitis and preparation method thereof | |
| CN103341059A (en) | Chinese medicine composition for treating non-gonococcal urethritis | |
| CN103550708B (en) | Chinese herbal compound for treating dysmenorrheal | |
| CN101721437B (en) | Preparation method of pharmaceutical composition for treating chronic pharyngitis | |
| CN104352910A (en) | Traditional Chinese medicine external suppository for treating women morbid leucorrhea and preparation method thereof | |
| CN101279084B (en) | Chinese medicine for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN103721191A (en) | Traditional Chinese medicinal enema for treating female chronic pelvic inflammation and preparation method thereof | |
| CN102335284B (en) | Externally applied health care product for recovery of female cauliflower excrescence | |
| CN102225154B (en) | Medicament composition for treating pulmonary fibrosis | |
| CN102198191B (en) | Quick acting medicine for treating prostate and urinary system infections, and production process thereof | |
| CN101607009B (en) | A pharmaceutical composition for treating common cold | |
| CN102018849A (en) | Traditional Chinese medicine composition for preventing irregular menstruation and preparation method thereof | |
| CN101468124A (en) | Chinese medicinal composition for preventing and treating menoxenia and method for preparing the same | |
| CN100333747C (en) | Medicine for treating pelvic inflammation and its producing method | |
| CN102727742A (en) | Sealwort-ginseng particles and preparation technology thereof | |
| CN1180835C (en) | Medicine for treating dysmenorrhea and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG XIANGYU HEALTH PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LIN FANYOU Effective date: 20140714 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140714 Address after: 276023 No. 30, Hangzhou Road, Linyi economic and Technological Development Zone, Linyi, Shandong Patentee after: Shandong Xiangyu Health Pharmaceutical Co., Ltd. Address before: 276023 Beijing road Shandong Linyi Province, Linyi City Economic Development Zone No. 30 Shandong Xiangyu Health Pharmaceutical Co. Ltd. Patentee before: Lin Fanyou |
|
| C56 | Change in the name or address of the patentee |
Owner name: XIANGYU PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SHANDONG XIANGYU HEALTH PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 276023 No. 30, Hangzhou Road, Linyi economic and Technological Development Zone, Linyi, Shandong Patentee after: Xiang Yu Pharmaceutical limited company Address before: 276023 No. 30, Hangzhou Road, Linyi economic and Technological Development Zone, Linyi, Shandong Patentee before: Shandong Xiangyu Health Pharmaceutical Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130213 Termination date: 20190928 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |